Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
Theme of Heart and Vessels, Karolinska University Hospital, Stockholm, Sweden.
J Intern Med. 2018 Apr;283(4):380-391. doi: 10.1111/joim.12723. Epub 2018 Feb 12.
Left ventricular (LV) mechanics have been extensively investigated in heart failure with preserved ejection fraction (HFpEF) overshadowing for a long time the potential role of left atrium (LA) in that setting. Soluble suppression of tumorigenicity-2 receptor (ST2) is a novel biomarker of pro-fibrotic burden in HF. We hypothesized that due to the thinner LA wall, the fibrotic myocardial changes in HFpEF as indicated by elevated ST2 levels might more readily be reflected by impairments in the LA rather than the LV performance.
In 86 patients with HFpEF, enrolled in the Karolinska Rennes (KaRen) biomarker prospective substudy, global LA strain (GL-LS) along with other echocardiographic as well as haemodynamic parameters and ST2 levels were measured. ST2 levels were inversely associated with LA-GS (r = -0.30, P = 0.009), but not with LA size, LV geometry, systolic or diastolic LV function (P > 0.05 for all). Furthermore, symptom severity correlated with ST2 and LA-GS, but not with LV structural or functional indices. Finally, during a median 18-month follow-up, LA-GS independently predicted the composite endpoint of HF hospitalization and all-cause mortality, even after adjustment for potential clinical and cardiac mechanical confounders, including LV global longitudinal strain and filling pressures (odds ratio: 4.15; confidence interval: 1.2-14, P = 0.023).
Reduced LA-GS but not LV functional systolic and diastolic parameters were associated with the pro-fibrotic ST2 marker, HF symptoms and outcome in HFpEF.
左心室(LV)力学在射血分数保留型心力衰竭(HFpEF)中得到了广泛研究,长期以来掩盖了左心房(LA)在该环境中的潜在作用。可溶性肿瘤抑制基因 2 受体(ST2)是心力衰竭中促纤维化负担的新型生物标志物。我们假设,由于 LA 壁较薄,HFpEF 中升高的 ST2 水平所指示的纤维化心肌变化可能更容易通过 LA 而不是 LV 功能障碍来反映。
在 86 名 HFpEF 患者中,他们参加了 Karolinska Rennes(KaRen)生物标志物前瞻性子研究,测量了整体 LA 应变(GL-LS)以及其他超声心动图和血流动力学参数和 ST2 水平。ST2 水平与 LA-GS 呈负相关(r=-0.30,P=0.009),但与 LA 大小、LV 几何形状、收缩或舒张 LV 功能无关(所有 P>0.05)。此外,症状严重程度与 ST2 和 LA-GS 相关,但与 LV 结构或功能指数无关。最后,在中位 18 个月的随访期间,即使在调整潜在的临床和心脏机械混杂因素(包括 LV 整体纵向应变和充盈压)后,LA-GS 仍独立预测 HF 住院和全因死亡率的复合终点(优势比:4.15;95%置信区间:1.2-14,P=0.023)。
在 HFpEF 中,LA-GS 的降低与促纤维化的 ST2 标志物、HF 症状和结局相关,而不是 LV 功能的收缩和舒张参数。